Bortezomib in the Treatment of Multiple Myeloma (Hardcover, Edition.)

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways. This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.

General

Imprint:	Birkhauser Verlag AG
Country of origin:	Switzerland
Series:	Milestones in Drug Therapy
Release date:	November 2010
First published:	2011
Editors:	Irene M Ghobrial • Paul G. Richardson • Kenneth C. Anderson
Dimensions:	235 x 155 x 13mm (L x W x T)
Format:	Hardcover
Pages:	180
Edition:	Edition.
ISBN-13:	978-3-7643-8947-5
Categories:	Books > Medicine > Clinical & internal medicine > Haematology Books > Medicine > Other branches of medicine > Pharmacology > General Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > Chemotherapy
LSN:	3-7643-8947-8
Barcode:	9783764389475

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!